1. Academic Validation
  2. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

  • J Transl Med. 2008 Oct 16;6:59. doi: 10.1186/1479-5876-6-59.
Elizabeth A DiBlasio-Smith 1 Maya Arai Elaine M Quinet Mark J Evans Tad Kornaga Michael D Basso Liang Chen Irene Feingold Anita R Halpern Qiang-Yuan Liu Ponnal Nambi Dawn Savio Shuguang Wang William M Mounts Jennifer A Isler Anna M Slager Michael E Burczynski Andrew J Dorner Edward R LaVallie
Affiliations

Affiliation

  • 1 Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA. [email protected]
Abstract

Background: LXRs (Liver X Receptor alpha and beta) are nuclear receptors that act as ligand-activated transcription factors. LXR activation causes upregulation of genes involved in reverse Cholesterol transport (RCT), including ABCA1 and ABCG1 transporters, in macrophage and intestine. Anti-atherosclerotic effects of synthetic LXR agonists in murine models suggest clinical utility for such compounds.

Objective: Blood markers of LXR Agonist exposure/activity were sought to support clinical development of novel synthetic LXR modulators.

Methods: Transcript levels of LXR target genes ABCA1 and ABCG1 were measured using quantitative Reverse Transcriptase/polymerase chain reaction assays (qRT-PCR) in peripheral blood from mice and rats (following a single oral dose) and monkeys (following 7 daily oral doses) of synthetic LXR agonists. LXRalpha, LXRbeta, ABCA1, and ABCG1 mRNA were measured by qRT-PCR in human peripheral blood mononuclear cells (PBMC), monocytes, T- and B-cells treated ex vivo with WAY-252623 (LXR-623), and protein levels in human PBMC were measured by Western blotting. ABCA1/G1 transcript levels in whole-blood RNA were measured using analytically validated assays in human subjects participating in a Phase 1 SAD (Single Ascending Dose) clinical study of LXR-623.

Results: A single oral dose of LXR agonists induced ABCA1 and ABCG1 transcription in rodent peripheral blood in a dose- and time-dependent manner. Induction of gene expression in rat peripheral blood correlated with spleen expression, suggesting LXR gene regulation in blood has the potential to function as a marker of tissue gene regulation. Transcriptional response to LXR Agonist was confirmed in primates, where peripheral blood ABCA1 and ABCG1 levels increased in a dose-dependent manner following oral treatment with LXR-623. Human PBMC, monocytes, T- and B cells all expressed both LXRalpha and LXRbeta, and all cell types significantly increased ABCA1 and ABCG1 expression upon ex vivo LXR-623 treatment. Peripheral blood from a representative human subject receiving a single oral dose of LXR-623 showed significant time-dependent increases in ABCA1 and ABCG1 transcription.

Conclusion: Peripheral blood cells express LXRalpha and LXRbeta, and respond to LXR Agonist treatment by time- and dose-dependently inducing LXR target genes. Transcript levels of LXR target genes in peripheral blood are relevant and useful biological indicators for clinical development of synthetic LXR modulators.

Figures
Products